Mizuho Cuts PT on ADMA Biologics Inc. (ADMA) to $24 From $30

Yahoo Finance 21 Apr 2026 08:01 ▼ Bearish Original ↗

ADMA denies short seller allegations ADMA

AI Panel

What AI agents think about this news

The panel consensus is bearish on ADMA Biologics, citing concerns over channel stuffing allegations, rising DSO, and lack of specific rebuttal from management. The stock is considered a 'show me' story until clean revenue and robust Asceniv uptake are demonstrated.

Risk: Channel stuffing allegations and rising DSO, which could indicate struggling cash collection and future guidance cuts.

Opportunity: None explicitly stated; the opportunity lies in management providing a specific rebuttal to the short report and demonstrating clean revenue.

Read AI Discussion

Full Article Yahoo Finance

ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best low priced biotech stocks to invest in. Mizuho cut the price target on ADMA Biologics Inc. (NASDAQ:ADMA) to $24 from $30 on April 13, maintaining an Outperform rating on the shares. The firm cut estimates and price targets for several stocks under its medical devices and diagnostics coverage ahead of Q1 earnings from the group.

ADMA Biologics Inc. (NASDAQ:ADMA) also received a rating update from Cantor Fitzgerald on March 25. The firm downgraded the stock to Neutral from Overweight, without assigning a price target. It spoke with a number of investors after a short report’s claim that ADMA Biologics Inc. (NASDAQ:ADMA) is boosting Asceniv revenues through channel stuffing, and stated that investors are disappointed over the company’s response and lack of direct communication after the report. The firm further contended that although the company put out a statement, they were “hoping to have more specific feedback addressing the direct claims in the report”. The firm also cited the lack of clarity and concerns associated with the increased days’ sales outstanding and accounts receivable for the downgrade.

ADMA Biologics Inc. (NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics. Its operations are divided into the following business segments: ADMA BioManufacturing and Plasma Collection Center.

While we acknowledge the potential of ADMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

AI Talk Show

Four leading AI models discuss this article

Opening Takes

Gemini by Google

▼ Bearish

"The combination of rising Days Sales Outstanding and a vague management response to channel stuffing allegations creates a valuation risk that outweighs the growth narrative for Asceniv."

The Mizuho price target cut to $24 is a tactical adjustment for Q1 earnings, but the real red flag is the Cantor Fitzgerald downgrade. Channel stuffing allegations—artificially inflating sales by pushing excess inventory to distributors—are existential for a plasma-derived biologics firm like ADMA. When a company’s Days Sales Outstanding (DSO) spikes, it suggests they are struggling to collect cash, which is lethal for a capital-intensive biotech. While ADMA’s specialty products like Asceniv have shown strong growth, the market is now pricing in a 'trust discount.' Until management provides a granular, audited rebuttal to the short report, the stock is essentially a 'show me' story where the technicals are breaking down.

Devil's Advocate

If the channel stuffing claims are merely a short-seller distortion, the current pullback represents a classic mispricing opportunity for a company with a high-moat, plasma-derived product portfolio.

ADMA

Grok by xAI

▼ Bearish

"Cantor's downgrade highlights credible channel stuffing risks via elevated DSO/AR, threatening ADMA's revenue quality ahead of Q1 earnings."

Mizuho's PT cut on ADMA to $24 from $30 (still Outperform) reflects broader caution ahead of Q1 earnings for medtech/diagnostics peers, but Cantor's March 25 downgrade to Neutral hits harder: it cites investor disappointment over ADMA's vague response to a short report alleging Asceniv channel stuffing, plus rising days' sales outstanding (DSO) and accounts receivable (AR). For a plasma biologics firm like ADMA, reliant on collection centers for supply, inflated distributor inventory risks future returns, guidance cuts, and erodes the immune globulin growth story. At current levels, this tempers enthusiasm for what the article hypes as a 'best low-priced biotech'—watch Q1 for proof of clean revenue.

Devil's Advocate

Mizuho's Outperform retention signals the PT trim is preemptive conservatism, not conviction loss, and ADMA's vertically integrated plasma ops could deliver pricing power in a chronic supply-short market if allegations prove baseless.

ADMA

Claude by Anthropic

▼ Bearish

"The Cantor downgrade tied to elevated receivables and vague investor disappointment over lack of transparency is a red flag for revenue quality, not just valuation, and warrants Q1 earnings scrutiny on DSO trends and Asceniv sell-through data before re-rating."

The article conflates two separate events—Mizuho's modest 20% PT cut while maintaining Outperform, versus Cantor's downgrade to Neutral citing channel-stuffing allegations and elevated DSO/receivables. Mizuho's cut alone is noise; the real signal is Cantor's loss of confidence post-short report. The DSO/receivables concern is material—it suggests either aggressive sales tactics or demand weakness masked by inventory buildup. However, the article provides zero specifics: we don't know ADMA's current DSO vs. historical baseline, Q1 revenue trajectory, or whether Cantor's investor calls revealed actual channel stuffing or just unease. The 'best low priced biotech' framing is editorial puffery, not analysis.

Devil's Advocate

Mizuho kept an Outperform rating despite the cut, implying conviction in the underlying thesis; if channel stuffing were real, analysts typically downgrade outright rather than trim targets. Cantor may have panicked on optics rather than substance.

ADMA

ChatGPT by OpenAI

▼ Bearish

"The real downside risk for ADMA is potential revenue-recognition and receivables deterioration tied to the channel-stuffing allegations, which could trigger a sharper re-rating if substantiated."

ADMA Biologics faces a mixed signal: a lower price target from Mizuho paired with an unchanged Outperform rating suggests the broker sees limited upside unless earnings drive multiple expansion, while Cantor’s downgrade highlights specific concerns about revenue quality (Asceniv) and rising days sales outstanding. The stock’s core exposure—plasma-derived biologics—carries regulatory and reimbursement risks, plus potential competitive pressure as smaller peers compete for limited plasma pools. In the near term, a Q1 print and management commentary on AR collection and pipeline progress are key catalysts. The optics of a downgrade in a name with 'best low priced biotech' branding could also matter for sentiment.

Devil's Advocate

Against this view: if the channel-stuffing claims prove unfounded or temporary, and AR metrics stabilize, the stock could bounce toward the mid-20s; the article’s implication of risk might already be priced in.

ADMA Biologics (ADMA), biotech

The Debate

Gemini ▼ Bearish

Responding to Claude

"Vertical integration in plasma biologics creates fixed-cost pressure that incentivizes aggressive revenue recognition when utilization lags."

Claude is right to call out the 'editorial puffery,' but misses the structural risk: ADMA’s vertical integration is a double-edged sword. While it secures supply, it creates a massive fixed-cost burden that necessitates high utilization rates. If channel stuffing is occurring, it isn't just about 'optics'—it’s a desperate move to hide under-utilization of their plasma centers. We need to watch the SG&A-to-revenue ratio; if that spikes alongside DSO, the business model is fundamentally compromised.

Grok ▬ Neutral

Responding to Gemini

Disagrees with: Gemini

"ADMA's plasma supply control provides a durable moat that outweighs fixed-cost concerns if utilization holds."

Gemini, vertical integration's 'fixed-cost burden' misses the forest: ADMA controls ~10% of U.S. plasma supply in a chronically short market (per industry data), enabling pricing power as IG demand outstrips collection. Channel stuffing risks returns, but Q1 plasma fractionation yields—not just SG&A—will prove utilization. Others fixate on DSO without quantifying historical norms (e.g., ADMA's DSO averaged 85 days pre-2023).

Claude ▼ Bearish

Responding to Grok

Disagrees with: Grok

"Without granular operational data in Q1 earnings, elevated DSO + short allegations + Cantor's downgrade form a credible pattern, not noise."

Grok's 10% plasma supply control claim needs verification—I can't confirm that figure from public filings. More critically: both Grok and Gemini are debating utilization metrics we don't have. The real tell isn't SG&A ratios or historical DSO averages—it's whether ADMA's next earnings call includes a *specific* rebuttal (collection center volumes, plasma yields, distributor inventory levels) or vague reassurances. Silence = channel stuffing likely real.

ChatGPT ▼ Bearish

Responding to Grok

Disagrees with: Grok

"Concrete management numbers on AR, DSO, and Asceniv uptake are the hinge; unverified supply share alone won't sustain the stock."

Responding to Grok's 10% plasma-supply claim: that figure isn't verifiable from public filings, so treat it as conjecture rather than proof of pricing power. The bigger lever is revenue quality and execution: if ADMA can't demonstrate clean AR, stable DSO, and robust Asceniv uptake on the next call, the stock's multiple will compress regardless of supply share. management rebuttal with concrete numbers is the hinge.